CareDx, Inc (CDNA)
NASDAQ: CDNA · IEX Real-Time Price · USD
18.09
-0.05 (-0.28%)
At close: Jul 19, 2024, 4:00 PM
18.37
+0.28 (1.55%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
CareDx Revenue
CareDx had revenue of $275.11M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $72.05M. In the year 2023, CareDx had annual revenue of $280.32M.
Revenue (ttm)
$275.11M
Revenue Growth
-13.93%
P/S Ratio
3.42
Revenue / Employee
$427,855
Employees
643
Market Cap
942.20M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
Dec 31, 2019 | 127.07M | 50.50M | 65.95% |
Dec 31, 2018 | 76.57M | 28.25M | 58.45% |
Dec 31, 2017 | 48.32M | 7.69M | 18.93% |
Dec 31, 2016 | 40.63M | 12.49M | 44.37% |
Dec 31, 2015 | 28.14M | 838.00K | 3.07% |
Dec 31, 2014 | 27.31M | 5.21M | 23.57% |
Dec 31, 2013 | 22.10M | 1.65M | 8.05% |
Dec 31, 2012 | 20.45M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
HealthStream | 282.88M |
BioLife Solutions | 137.30M |
Cronos Group | 93.03M |
Bicycle Therapeutics | 41.61M |
Silence Therapeutics | 33.86M |
AnaptysBio | 22.96M |
CDNA News
- 5 days ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA) - PRNewsWire
- 6 days ago - CareDx to Report Second Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients - Business Wire
- 7 weeks ago - AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress - Business Wire
- 7 weeks ago - CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant - Business Wire
- 7 weeks ago - CareDx to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies - Business Wire
- 2 months ago - CareDx Reports First Quarter 2024 Results - Business Wire